Pulsatile insulin of Medicine at the University of California, Davis, led the field as a pioneer of using pulsatile insulin in the treatment of diabetes. Dr. Aoki’s work focused on the role of liver dysfunction in diabetic metabolism. He theorized that end organ damage in diabetes is caused by abnormal hepatic glucose metabolism, inadequate insulin delivery, and insulin resistance. He called his approach Metabolic Activation Therapy (MAT), which consisted of an ever-increasing baseline of insulin using Respiratory Quotient to determine the efficiency of treatment (US Patent 4,826,810). Normally, insulin is secreted from the pancreas in pulses into the portal vein which brings
Insulin pump being injected, or if the cannula becomes bent or kinked in the body, preventing delivery. Therefore, pump users typically monitor their blood sugars more frequently to evaluate the effectiveness of insulin delivery. Use of insulin pumps is increasing because of: In 1963 Dr. Arnold Kadish designed the first insulin pump to be worn as a backpack. A more wearable version was later devised by Dean Kamen in 1976. Kamen formed a company called "AutoSyringe" to market the product, which he sold to Baxter Health Care in 1981. The insulin pump was first endorsed in the United Kingdom in 2003, by